<h4>Background</h4>Therapeutic options and biomarkers for isocitrate dehydrogenase-mutated (IDHmut) diffuse lower-grade glioma (dLGG), WHO grade 2-3, are limited. Here, IDH3A is linked to central nervous system cancer.